AbbVie Inc.

AbbVie is the diversified big-pharma name that owns Humira, Skyrizi, Rinvoq, and a growing immunology/oncology stack, plus Botox and the eye-care franchise. The whole story for the past three years has been whether Skyrizi and Rinvoq could grow fast enough to offset the Humira patent cliff — the answer is now clearly yes, and the stock is up 28% over the past year with fresh analyst target raises still coming.

Where the mechanics actually land:

• Growth is real and re-accelerating: Q1 revenue grew 12.4% year-on-year to $15B on a 32% operating margin and 72% gross margin — those are elite-tier pharma economics, and the trailing four EPS beats have averaged 2-5% above consensus consistently.
• Management is actively spending to grow: $11B in business-development spend since the start of 2026, capped by the June 22 all-cash acquisition of Apogee Therapeutics at $135.11 per share — this expands the immunology and pipeline stack materially and is being funded from cash without meaningful dilution.
• Analyst tape is confirming: BofA moved to $276, Wells Fargo lifted to $295, both citing durable growth and easing loss-of-exclusivity concerns — and TEPKINLY just got European Commission approval in relapsed/refractory follicular lymphoma, another oncology tailwind.
• The valuation is where the risk sits: 110x trailing P/E is a distorted reading (impacted by acquired IPR&D charges), but 18x forward P/E on 15% expected EPS growth is a more useful frame — and the just-flagged $291M Q2 IPR&D hit ($0.17 EPS drag) is real one-time noise into the print.

The July 31 earnings is the near-term test — a beat with Skyrizi/Rinvoq growth still accelerating and clean 2026 guidance despite the IPR&D charges is what powers the run toward $295 targets, while any hint of Skyrizi share loss or a Rinvoq safety event is what would compress the multiple back toward the pharma-index average.